▶ IPA / CJC-1295 · SUBTOPIC · SAFETY PROFILE
IPA / CJC-1295 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of IPA / CJC-1295.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of IPA / CJC-1295. Severity, frequency, and attribution depend on the source publication.
- Injection-site reactions
- Mild flushing
- Transient hunger (ipamorelin component)
- Rare water retention
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for IPA / CJC-1295.
- Concurrent rhGH not recommended
- Insulin / glucose-lowering agents (mild hyperglycemia possible)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for IPA / CJC-1295 in the published record:
- Active malignancy
- Pituitary tumor
- Pregnancy/lactation
FDA REGULATORY STATUS
Not FDA-approved. Sponsored Phase 2 program for ipamorelin (postoperative ileus) discontinued. CJC-1295 with-DAC ConjuChem program halted.
WADA REGULATORY STATUS
Both prohibited at all times under WADA Section S2. Ipamorelin in the growth-hormone-secretagogue sub-category. CJC-1295 in the GHRH-analog sub-category.
SAFETY Q+A FROM LITERATURE
▶ Is ipamorelin FDA-approved?
No. The Helsinn/the originator pharma sponsor Phase 2 ipamorelin program for postoperative ileus (Beck et al. 2014, PMID 25331030) was discontinued. No subsequent FDA approval.
▶ Are ipamorelin and CJC-1295 banned in sports?
Yes. Both are prohibited at all times under WADA Section S2 · ipamorelin in the growth-hormone-secretagogue sub-category, CJC-1295 in the GHRH-analog sub-category.
▶ Side effects of ipamorelin / CJC-1295?
Most common in community-reported research protocols: mild injection-site reactions, transient hunger (ghrelin-receptor component), mild flushing, rare water retention. Safer profile than older non-selective GHS like GHRP-6.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 2009. PMID 19289567. link
- Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19